8-KMaterial AgreementsRegulation FDExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Material Agreement (May 21, 2010)

Filed May 21, 2010For Securities:ABT

Summary

This Form 8-K filing by Abbott Laboratories (ABT) on May 21, 2010, announces a significant strategic acquisition. Abbott's subsidiary, Abbott Healthcare Private Limited, has entered into a definitive Business Transfer Agreement to acquire Piramal Healthcare Limited's Healthcare Solutions business (Domestic Formulations). This acquisition represents a substantial investment for Abbott, with an up-front payment of $2.12 billion, followed by four annual payments of $400 million starting in 2011. The deal is a key step in expanding Abbott's presence in the pharmaceutical market, particularly in the domestic formulations segment. Investors should note that the transaction is subject to customary closing conditions, including Piramal's shareholder approval and regulatory clearances.

Key Highlights

  • 1Abbott Laboratories acquired Piramal Healthcare's Healthcare Solutions business (Domestic Formulations).
  • 2The acquisition was executed through Abbott's subsidiary, Abbott Healthcare Private Limited.
  • 3The total transaction value includes an initial payment of $2.12 billion.
  • 4Additional payments of $400 million annually for four years will be made starting in 2011.
  • 5The agreement is subject to Piramal shareholder approval and regulatory approvals.
  • 6The deal aims to expand Abbott's market presence in the domestic pharmaceutical formulations sector.
  • 7The filing includes the Business Transfer Agreement and a press release as exhibits.

Frequently Asked Questions

This 8-K filing announces Abbott Laboratories' definitive agreement to acquire Piramal Healthcare Limited's Healthcare Solutions business (Domestic Formulations). It details the key terms of the acquisition, including the purchase price and conditions.

The total financial commitment includes an up-front payment of $2.12 billion, plus an additional $400 million per year for four years, beginning in 2011. This brings the potential total consideration to $3.72 billion.

Yes, the acquisition is subject to several conditions, including the approval of Piramal's shareholders, customary closing conditions, and necessary regulatory approvals.

This acquisition specifically targets Piramal's Healthcare Solutions business, focusing on its domestic formulations segment, which is expected to enhance Abbott's market reach in this area.